Elisigen (formerly Neuracle Genetics) has received approval from Health Canada for its Phase 1/2a clinical trial of 'NG101', an AAV-based gene therapy for wet Age-related Macular Degeneration (wAMD). This trial marks a significant milestone in evaluating the safety and tolerability of NG101.
Read Original Article (Korean)
*Note: This link will redirect you to the original source in Korean.